Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy-Reference-Cited by-同舟云学术

Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy

Published:2011-02 Issue:1 Volume:11 Page:54-59
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Faderl Stefan,Thomas Deborah Ann,O'Brien Susan,Ravandi Farhad,Garcia-Manero Guillermo,Borthakur Gautam,Ferrajoli Alessandra,Verstovsek Srdan,Ayoubi Mohamed,Rytting Michael,Feliu Jennie,Kantarjian Hagop M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference17 articles.

1. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia;Nachman;Br J Haematol,2005

2. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies;Stock;Blood,2008

3. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia;DeAngelo;Blood,2007

4. Pediatric-based therapy for young adults with newly diagnosed lymphoblastic leukemia;Rytting;Blood,2009

5. High dose intensive chemotherapy, as is standard in childhood leukemia, is feasible and efficacious in adult with acute lymphoblastic leukemia (ALL) up to the age of 40: results from the Dutch-Belgian HOVON-70 study;Rijneveld;Blood,2009

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging innovations in vincristine-encapsulated nanoparticles: Pioneering a new era in oncological therapeutics;Journal of Drug Delivery Science and Technology;2024-01

2. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis;Clinical Therapeutics;2024-01

3. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia;Cancer Medicine;2023-11-13

4. Vincristine-based nanoformulations: a preclinical and clinical studies overview;Drug Delivery and Translational Research;2023-08-08

5. Altered physical phenotypes of leukemia cells that survive chemotherapy treatment;Integrative Biology;2023